can type 1 diabetics use glp 1 GLP-1 and GIP in Diabetes Therapy: A Time for Reappraisal? GLP-1 for Weight Loss and

Contrast this with Semaglutide, where trials showed an average loss of about 15% over a similar period

By far, the most common side effects are gastrointestinal, specifically nausea, vomiting, diarrhea, and constipation

Buy in the UK: Solgar Pantothenic Acid

By Product: Ozempic dominates, Tirzepatide products growing fastest Ozempic (semaglutide 0.5mg/1mg/2mg weekly subcutaneous injection) dominated the GLP-1 receptor agonist market with approximately 35.12% market share in 2025, driven by its combination of robust clinical efficacy data, early market entry, broad diabetes label, established prescriber relationships, and expanded off-label use for weight management before Wegovy's commercial scale-up